En tant que substrat à risque du CYP3A4

(abémaciclib, alfentanil, apixaban, atorvastatine, axitinib, bortezomib, bosutinib, brigatinib, cabazitaxel, cabozantinib, céritinib, ciclosporine, cobimétinib, crizotinib, dabrafénib, dasatinib, dihydroergotamine, docetaxel, ergotamine, erlotinib, everolimus, gefitinib, halofantrine, ibrutinib, imatinib, irinotecan, lapatinib, lorlatinib, lumefantrine, midazolam, nilotinib, osimertinib, oxycodone, paclitaxel, palbociclib, pazopanib, pimozide, ponatinib, quetiapine, quinine, rivaroxaban, ruxolitinib, simvastatine, sirolimus, sorafenib, sufentanil, sunitinib, tacrolimus, temsirolimus, ticagrelor, vandétanib, vinblastine, vincristine, vindesine, vinflunine, vinorelbine)